AEMD AETHLON MED INC revenue, earnings and financials
For the quarter ended June 30, 2026, AETHLON MED INC reported revenue of n/a, net income of −$1.55M and diluted EPS of −$4.02; for the fiscal year ended March 2026 revenue was n/a.
AEMD annual revenue and earnings
- Fiscal year ended Mar 2026: revenue n/a, gross profit n/a, operating income −$7.29M, net income −$7.15M (margin n/a), EPS −$10.61
- Fiscal year ended Mar 2025: revenue n/a, gross profit n/a, operating income −$9.34M, net income −$13.4M (margin n/a), EPS −$85.77
- Fiscal year ended Mar 2024: revenue $0, gross profit n/a, operating income −$12.6M, net income −$12.2M (margin n/a), EPS −$38.87
- Fiscal year ended Mar 2023: revenue $574K, gross profit n/a, operating income −$11.9M, net income −$12.0M (margin -2094.9%), EPS −$5.86
- Fiscal year ended Mar 2022: revenue $294K, gross profit n/a, operating income −$10.4M, net income −$10.4M (margin -3540.9%), EPS −$0.71
AEMD quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$1.55M, EPS −$4.02
- Quarter ended Mar 31, 2026 (from the annual report): revenue n/a, net income −$1.88M, EPS $38.00
- Quarter ended Dec 31, 2025: revenue n/a, net income −$2.02M, EPS −$2.45
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.49M, EPS −$3.74
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.76M, EPS −$42.42
- Quarter ended Mar 31, 2025 (from the annual report): revenue n/a, net income −$6.27M, EPS −$56.85
- Quarter ended Dec 31, 2024: revenue n/a, net income −$1.75M, EPS −$10.05
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.81M, EPS −$16.11
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.57M, EPS −$2.76
- Quarter ended Mar 31, 2024 (from the annual report): revenue n/a, net income −$2.43M, EPS −$34.93
- Quarter ended Dec 31, 2023: revenue n/a, net income −$3.47M, EPS −$1.37
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.03M, EPS −$1.22
- Quarter ended Jun 30, 2023: revenue n/a, net income −$3.28M, EPS −$1.35
- Quarter ended Mar 31, 2023 (from the annual report): revenue $574K (up 4278.2% year over year), net income −$2.47M, EPS −$2.59
- Quarter ended Dec 31, 2022: revenue $0 (down 100.0% year over year), net income −$2.85M, EPS −$1.24
- Quarter ended Sep 30, 2022: revenue $0 (down 100.0% year over year), net income −$3.81M, EPS −$1.84
- Quarter ended Jun 30, 2022: revenue $0 (down 100.0% year over year), net income −$2.91M, EPS −$0.19
- Quarter ended Mar 31, 2022 (from the annual report): revenue $13.1K, net income −$3.79M, EPS −$0.26
- Quarter ended Dec 31, 2021: revenue $17.1K, net income −$2.53M, EPS −$0.16
- Quarter ended Sep 30, 2021: revenue $132K, net income −$2.01M, EPS −$0.13
AEMD cash flow, buybacks and dividends
- Fiscal year ended Mar 2026: operating cash flow −$7.00M, share buybacks n/a
- Fiscal year ended Mar 2025: operating cash flow −$7.65M, share buybacks n/a
- Fiscal year ended Mar 2024: operating cash flow −$10.1M, share buybacks n/a
- Fiscal year ended Mar 2023: operating cash flow −$10.5M, share buybacks n/a
- Fiscal year ended Mar 2022: operating cash flow −$9.77M, share buybacks n/a
AEMD balance sheet
- Jun 30, 2026: cash $4.93M, total assets $6.24M, total liabilities n/a, shareholders' equity $5.20M
- Mar 31, 2026: cash $5.03M, total assets $6.33M, total liabilities $1.45M, shareholders' equity $4.89M
- Dec 31, 2025: cash $6.96M, total assets $8.06M, total liabilities $1.34M, shareholders' equity $6.71M
- Sep 30, 2025: cash $5.85M, total assets $7.32M, total liabilities $1.58M, shareholders' equity $5.75M
- Jun 30, 2025: cash $3.77M, total assets $5.31M, total liabilities $1.88M, shareholders' equity $3.42M
- Mar 31, 2025: cash $5.50M, total assets $7.36M, total liabilities $2.24M, shareholders' equity $5.12M
- Dec 31, 2024: cash $4.83M, total assets $6.53M, total liabilities $2.19M, shareholders' equity $4.33M
- Sep 30, 2024: cash $6.86M, total assets $8.85M, total liabilities $2.83M, shareholders' equity $6.02M
Is AEMD profitable?
No. AETHLON MED INC lost $6.94M over the last four quarters.
What is AEMD's EPS?
Diluted earnings per share over the last four quarters were $27.79; −$4.02 in the latest quarter.